# Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma

> **NCT03200691** · PHASE2 · UNKNOWN · sponsor: **Hangzhou Cancer Hospital** · enrollment: 21 (estimated)

## Conditions studied

- Esophageal Neoplasms
- Esophageal Diseases

## Interventions

- **RADIATION:** 3-DCRT or IMRT radiation
- **DRUG:** anti-PD-1 antibody SHR-1210

## Key facts

- **NCT ID:** NCT03200691
- **Lead sponsor:** Hangzhou Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-10
- **Primary completion:** 2018-06-30
- **Final completion:** 2020-07-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2017-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03200691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03200691, "Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03200691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*